Image de couverture de livre

Acute anti‐Aβ antibody exposure induces microglial changes and significantly alters chemokine signaling

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Kate E. Foley, Erica M. Weekman, Donna M. Wilcock
Format:	Artículo Open Access
Publié:	Wiley 2026
Sujets:	Alzheimer's & Dementia: Translational Research & Clinical Interventions
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Clinical efficacy of anti‐amyloid antibodies in apolipoprotein E ε4 homozygotes: A Bayesian reanalysis of lecanemab and donanemab phase 3 results
par: Stefan Teipel, et autres
Publié: (2025)

Mapping brain change longitudinally: physical activity intervention reshapes structural alterations and functional connectivity in Alzheimer's disease
par: Ravi Dadsena, et autres
Publié: (2026)

Locus coeruleus alterations in dementia with Lewy bodies: A systematic review
par: Anaëlle Bain, et autres
Publié: (2026)

Worth their weight in gray matter? A narrative review of cost‐effectiveness analyses of monoclonal antibodies for Alzheimer's disease
par: Tuyet Thao Nguyen, et autres
Publié: (2026)

Combination therapy targeting Alzheimer's disease risk factors is associated with a significant delay in Alzheimer's disease–related cognitive decline
par: Yuan Shang, et autres
Publié: (2025)

Generating real‐world evidence in early Alzheimer's disease: Considerations for applying the target trial emulation framework to study the safety of anti‐amyloid therapies
par: Xiaojuan Li, et autres
Publié: (2025)

The association of cholesterol levels with memory and memory change over a 14‐year period in a US national cohort
par: Silvia Miramontes, et autres
Publié: (2025)

Alzheimer's disease drug development pipeline: 2025
par: Jeffrey L. Cummings, et autres
Publié: (2025)

Evaluation of amyloid change as a surrogate for cognitive decline: demonstration in individual‐level data from the A4 study of solanezumab
par: Sarah F. Ackley, et autres
Publié: (2026)

Digital biomarkers: Redefining clinical outcomes and the concept of meaningful change
par: Maria Florencia Iulita, et autres
Publié: (2025)

Optimized 5‐HT 2b inhibitors for neuropsychiatric syndromes with cognitive dysfunction
par: Saktimayee M. Roy, et autres
Publié: (2025)

Genetically proxied IL‐6 signaling and risk of Alzheimer's disease and lobar intracerebral hemorrhage: A drug target Mendelian randomization study
par: Evangelos Pavlos Myserlis, et autres
Publié: (2024)

Functional connectome metrics reveal distinct prognostic subtypes in two Phase 3 gantenerumab trials
par: Susanna Gobbi, et autres
Publié: (2026)

Meaningful benefit of disease‐modifying treatment: Evaluating changes in health‐related resource use
par: Carolyn W. Zhu, et autres
Publié: (2024)

Diabetes mellitus exacerbates changes in white matter hyperintensity shapes and volume: A longitudinal study
par: Shihao Xu, et autres
Publié: (2025)

Alzheimer's disease drug development pipeline: 2026
par: Jeffrey L. Cummings, et autres
Publié: (2026)

Commentary on Greenberg et al., “Prescribing anti‐amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions” [ Alzheimer's Dement . 2023; 9(4):e12426. doi.org/10.1002/trc2.12426]
par: Carl V. Hill, et autres
Publié: (2024)

Low intrinsic capacity is associated with a blunted exercise‐induced cognitive enhancement in physically active middle‐aged and older adults
par: Brandon A. Yates, et autres
Publié: (2025)

Chronic cerebral hypoperfusion‐induced myelin loss in normal‐appearing white matter correlates with cognitive decline: insights from moyamoya disease
par: Xinfeng Yu, et autres
Publié: (2025)

Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients
par: Dawn C. Matthews, et autres
Publié: (2024)

Programmatic research outcomes used to establish the evidence‐base of dementia caregiving support programs: An analysis of Best Programs for Caregiving
par: Morgan J. Minyo, et autres
Publié: (2025)

Pooling Alzheimer's disease clinical trial data to develop personalized medicine approaches is easier said than done: A proof‐of‐principle study and call to action
par: Mark A. Dubbelman, et autres
Publié: (2024)

A service‐oriented approach to clinical trial recruitment for dementia and brain health: Methods and case examples of MyAlliance for Brain Health
par: Eric D. Vidoni, et autres
Publié: (2024)

Bayesian meta‐analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high‐dose gantenerumab in prodromal and mild Alzheimer's disease
par: Stefan J. Teipel, et autres
Publié: (2024)

Evaluation of racial and ethnic heterogeneity in the associations of sleep quality and sleep apnea risk with cognitive function and cognitive decline
par: Ruijia Chen, et autres
Publié: (2024)

Utilizing MCID for evaluating clinical relevance of AD therapeutic interventions
par: Jamie L. Hamilton, et autres
Publié: (2025)

Directionality between cognitive function and daily physical activity patterns
par: Francesca R. Marino, et autres
Publié: (2025)

Leveraging recent advances in plasma biomarkers to optimize early proof of concept trials in Alzheimer's disease
par: Garrett B. Duncan, et autres
Publié: (2025)

Mitochondrial blood‐based biomarker is related to cardiorespiratory fitness and aging in a sex‐dependent manner
par: Riley E. Kemna, et autres
Publié: (2025)

Biomarkers in Alzheimer's disease clinical trials: 2025
par: Amanda M. Leisgang Osse, et autres
Publié: (2026)

Association between 24‐h time‐use composition and brain age: The IGNITE study
par: Audrey M. Collins, et autres
Publié: (2025)

Differential relationships between cardiorespiratory fitness and cortical thickness across the adult lifespan: A generalized additive model approach
par: Jillian H. Graham, et autres
Publié: (2026)

Unforgettable: The power of community in the pursuit of health equity for Alzheimer's disease and other dementia
par: Beverly M. Berry, et autres
Publié: (2025)

Promotores program to increase Hispanic/Latino(a) participation in Alzheimer's disease research
par: Zvinka Z. Zlatar, et autres
Publié: (2026)

Genetic and multi‐omic risk assessment of Alzheimer's disease implicates core associated biological domains
par: Gregory A. Cary, et autres
Publié: (2024)

Clinically meaningful outcomes in Alzheimer's disease and Alzheimer's disease related dementias trials
par: Luke E. Stoeckel, et autres
Publié: (2025)

Recruitment of mid‐life adults to a randomized clinical trial: The multicultural healthy diet study to reduce cognitive decline and Alzheimer's disease risk
par: Mindy J. Katz, et autres
Publié: (2025)

Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice
par: Clifford R. Jack, et autres
Publié: (2024)

Assessing social connection for long‐term care home residents: A scoping review of measure content
par: Madalena P. Liougas, et autres
Publié: (2024)

Communicating Alzheimer's biomarker results to cognitively unimpaired research participants: Satisfaction, utility, and impact on research attitudes
par: Claire M. Erickson, et autres
Publié: (2024)